Video
Dr. Klempner on the Investigation of Adagrasib in KRAS G12C–Mutated mCRC
Author(s):
Sam Klempner, MD, discusses the investigation of adagrasib in KRAS G12C–mutated metastatic colorectal cancer.
Sam Klempner, MD, faculty member, Oncology, Massachusetts General Hospital, Medicine, Harvard Medical School, discusses the investigation of adagrasib (MRTX849) in KRAS G12C–mutated metastatic colorectal cancer (mCRC).
Adagrasib is currently being evaluated in the phase 3 KRYSTAL-10 trial (NCT04793958) in patients with mCRC harboring a KRAS G12C mutation, Klempner says. Eligible patients progressed on at least 1 prior line of therapy, and those enrolled are randomly assigned to standard-of-care chemotherapy or treatment with adagrasib plus cetuximab (Erbitux), Klempner explains.
The co-primary end points of the trial are progression-free survival and overall survival, Klempner continues. The trial is expected to enroll approximately 420 patients, and it is currently open and accruing globally, Klempner concludes.
